

Ideal Cures to launch Instanute DR at Geneva event

22 May 2012 | News | By BioSpectrum Bureau

Ideal Cures to launch Instanute DR at Geneva event



Singapore: Indian pharmaceutical company Ideal Cures will launch its newly developed delayed release delivery system, Instanute DR, at the Vitafoods Europe event in Geneva. Mr Suresh Pareek, managing director and one of the inventors of the technology, said Instanute DR is a path-breaking product for delaying the release of active ingredients having wide applicability in nutraceutical, food and dietary supplement industry.

Instanute DR is a ready-to-use enteric coating product and will help in maintaining efficacy of the active ingredient sensitive to high acidic pH in stomach. Through the use of Instanute DR, scientists will be able to program the release profile of the active ingredients ranging from 20-120 minutes. This is the first time Alginate Acid based composition has been developed to delay the release of drugs by film coating.

Chetan Rajsharad, vice-president- R&D, Ideal Cures India, and one of the inventors based in Mumbai, said Instanute DR product is based on natural polymer that meets all regulatory requirements.

Instanute DR is already tested extensively on some products such as mint oil and fish oil soft-gel capsules exhibiting programmable release profile of 60 minutes to 120 minutes. It has also been tested on creatine and chili extract tablets for control release profile of 45 minutes to 60 minutes. Instanute DR is also experimented successfully in herbal products. Ten Herb tablet was showing delayed release profile of 60 minutes to 120 minutes.